Nuvectis Pharma (NVCT)
Develops licensed small-molecule programs across complement disease and kinase-targeted oncology.
Something off on this page? Send us feedback.
Develops licensed small-molecule drug candidates in one clinical-development segment: NXP100 for complement-mediated disease, NXP900 for SRC/YES1 kinase biology, and NXP200 for BRAF-mutated malignancies. Based in Fort Lee, the founder-led team relies on consultants, vendors, third-party manufacturers, and external capital to advance trials.
Develops a clinical-stage pipeline built around NXP100, NXP900, and NXP200. NXP100 is an oral complement Factor B inhibitor for complement-mediated diseases; NXP900 targets SRC and YES1 kinases in oncology; NXP200 is a brain-penetrant BRAF inhibitor for BRAF-mutated malignancies. NXP800 is no longer in active clinical development while next steps are assessed.
The business is reported as a single clinical-development segment and is based in Fort Lee, New Jersey. The Haisco license broadened the pipeline beyond the earlier oncology-only frame, with rights structured around territories outside Haisco's retained markets.
Execution depends on a small founder-led team using consultants, vendors, and third-party manufacturers. Product revenue requires further studies, regulatory review and approval, manufacturing access, commercialization buildout, and financing tied to the Haisco agreement.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Sep 1, 2026 | Loop Capital Markets | Target | $40 | ||
| Aug 24, 2026 | Cantor Fitzgerald | Initiate | Overweight | ||
| Jul 5, 2026 | UBS | Target | $33 | ||
| Jun 22, 2026 | H.C. Wainwright | Target | $13 | $39 | |
| Jun 12, 2026 | H.C. Wainwright | Target | $10 | $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $22.2M · Total debt $0 · Total assets $22.4M · Shareholders' equity $9.1M
- Revenue
- $0
- Operating income
- −$7.2M
- Net income
- −$7.0M
No dividends on record.
| Institutions63 holders · as of Mar 31, 2026 | 13.87% | 4.52M shares | |
| Insiders9 holders · as of Aug 5, 2026 | 42.70% | 13.91M shares | |
| Otherremainder | 43.43% | 14.15M shares |
32.58M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (32.58M in the company's Sep 3, 2026 report, 26.54M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Marlio Charles MosseriInsider10 percent owner | 17.90% | 5.83M | Form 4filed Jul 1, 2026 ↗ |
Ron BentsurInsiderdirector, 10 percent owner, officer: Chairman & CEO | 11.32% | 3.69M | Form 4filed Jul 1, 2026 ↗ |
Enrique PoradosuInsiderofficer: Chief Science & Business Off | 5.54% | 1.81M | Form 4filed Jan 9, 2026 ↗ |
Shay ShemeshInsiderofficer: Chief Dev. & Ops. Officer | 5.50% | 1.79M | Form 4filed Jan 9, 2026 ↗ |
BlackRock, Inc.Institution | 2.35% | 764,441 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 30, 2026 | Ron Bentsur | director, 10 percent owner, officer: Chairman & CEO | +12,500 | $20.00 |
| Jun 30, 2026 | Marlio Charles Mosseri | 10 percent owner | +50,000 | $18.32 |
| Nov 5, 2025 | Matthew L. Kaplan | director | +11,000 | $5.84 |
| Nov 5, 2025 | Juan Sanchez | director | +13,000 | $5.79 |
| Nov 5, 2025 | Ron Bentsur | director, 10 percent owner, officer: Chairman & CEO | +5,000 | $5.72 |
- Novartis (ADR)
Factor B and BRAF benchmark across NXP100 and NXP200
- AstraZeneca (ADR)
PNH complement incumbent with Soliris, Ultomiris, and Voydeya
- Pfizer
BOSULIF and BRAFTOVI overlap NXP900 and NXP200
- Bristol-Myers Squibb
SPRYCEL is a filing-named SRC/YES1 kinase comparator
- Ionis Pharmaceuticals
Factor B antisense program challenges the IgAN lane
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nuvectis Pharma | $24.00 | +4.08% | $634.8M | — | — | — | — |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| AstraZeneca (ADR) | $163.26 | +0.99% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Bristol-Myers Squibb | $67.65 | −0.01% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Ionis Pharmaceuticals | $60.74 | −0.93% | $10.19B | — | — | 11.7 | −40.7% |
| Median | 24.4 | 12.9 | 4.1 | +2.6% |